Withus Pharmaceutical Co. Ltd. (330350) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Withus Pharmaceutical Co. Ltd. (330350:KRX), powered by AI.

Current Price
₩8,180
P/E Ratio
21.7
Market Cap
108.0B
Sector
Healthcare
What is the Withus Pharmaceutical Co. Ltd. stock price forecast?

Withus Pharmaceutical Co. Ltd. is currently trading at ₩8,180. View real-time AI analysis on Alpha Lenz.

What is Withus Pharmaceutical Co. Ltd. insider trading activity?

View the latest insider trading data for Withus Pharmaceutical Co. Ltd. on Alpha Lenz.

What is Withus Pharmaceutical Co. Ltd.'s P/E ratio?

Withus Pharmaceutical Co. Ltd.'s P/E ratio is 21.7.

Withus Pharmaceutical Co. Ltd.

KRX · 330350
₩8,180+1,520(+22.82%)Market closedKRX regular session 09:00–15:30 KST
Ask about Withus Pharmaceutical Co. Ltd.'s future dividend policy...
Alpha Chat Insight

Withus Pharmaceutical Co. Ltd. trades at a P/E of 21.7 (fair value) with modest ROE of 5.2%. 3Y revenue CAGR of 18.1% highlights clear growth momentum.

Ask for details

Company Overview

Withus Pharmaceutical Co. Ltd. is a dynamic entity in the healthcare sector, primarily focusing on the development and production of pharmaceuticals and healthcare products. As a key player in the market, the company is actively engaged in research and development to bring innovative and effective therapeutic solutions to a broad spectrum of medical needs. Its product line spans various therapeutic areas, emphasizing quality and reliability, and is distributed across numerous channels including hospitals, pharmacies, and direct-to-consumer sales. With a commitment to enhancing health outcomes, Withus Pharmaceutical Co. Ltd. contributes significantly to the pharmaceutical industry's advancement. The company maintains stringent standards in its manufacturing processes and actively collaborates with healthcare professionals and institutions to ensure its products meet the highest safety and efficacy benchmarks. With its strategic positioning and continuous innovation, Withus Pharmaceutical Co. Ltd. plays a crucial role in the healthcare ecosystem, addressing the evolving challenges and demands of modern medicine.

CEO성대영
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩107,973,382,400Market Cap
₩106,444,236,300Revenue
13.20MShares Out
0Employees

Margins

64.66%Gross
11.26%EBITDA
5.32%Operating
4.24%Pre-Tax
4.67%Net

Valuation

21.74P/E
1.10P/B
1.01EV/Sales
9.12EV/EBITDA
29.45P/FCF

Growth (CAGR)

18.06%Rev 3Yr
15.23%Rev 5Yr
5.10%Op Inc 3Yr
-10.27%Op Inc 5Yr
26.07%Net Inc 3Yr
-9.18%Net Inc 5Yr

Returns

3.66%ROA
5.20%ROE
3.85%ROIC

Financial Health

₩17,389,615,390Cash & Cash Equivalents
₩21,248,386,780Net Debt
39.42%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Withus Pharmaceutical Co. Ltd. (ticker: 330350) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $108.0B.

The current price is ₩8,180 with a P/E ratio of 21.74x and P/B of 1.1x.

ROE is 5.20% and operating margin is 5.32%. Annual revenue is $106.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Withus Pharmaceutical Co. Ltd. (330350) Stock Forecast 2026 ₩8,180 — Price, Financials & Analyst Targets | Alpha Lenz